Compile Data Set for Download or QSAR
Report error Found 49 Enz. Inhib. hit(s) with all data for entry = 1960
TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347773(US9790220, Example 6)
Affinity DataIC50: 8.60nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347772(US9790220, Example 5)
Affinity DataIC50: 14nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347777(US9790220, Example 10)
Affinity DataIC50: 21nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347788(US9790220, Example 21)
Affinity DataIC50: 24nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347786(US9790220, Example 19)
Affinity DataIC50: 33nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347775(US9790220, Example 8)
Affinity DataIC50: 34nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347785(US9790220, Example 18)
Affinity DataIC50: 41nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347779(US9790220, Example 12)
Affinity DataIC50: 42nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347769(US9790220, Example 1)
Affinity DataIC50: 43nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347780(US9790220, Example 13)
Affinity DataIC50: 69nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 27 | US9790220, Example 26)
Affinity DataIC50: 71nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347776(US9790220, Example 9)
Affinity DataIC50: 84nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347791(US9790220, Example 24)
Affinity DataIC50: 86nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347787(US9790220, Example 20)
Affinity DataIC50: 100nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347770(US9790220, Example 2)
Affinity DataIC50: 128nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347782(US9790220, Example 15)
Affinity DataIC50: 150nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347771(US9790220, Example 3)
Affinity DataIC50: 170nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347781(US9790220, Example 14)
Affinity DataIC50: 170nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347784(US9790220, Example 17)
Affinity DataIC50: 210nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347790(US9790220, Example 23)
Affinity DataIC50: 290nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347789(US9790220, Example 22)
Affinity DataIC50: 300nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347778(US9790220, Example 11)
Affinity DataIC50: 330nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347774(US9790220, Example 7)
Affinity DataIC50: 540nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347783(US9790220, Example 16)
Affinity DataIC50: 630nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347792(US9790220, Example 25)
Affinity DataIC50: 660nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 27 | US9790220, Example 26)
Affinity DataIC50: 910nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347772(US9790220, Example 5)
Affinity DataIC50: 2.80E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347775(US9790220, Example 8)
Affinity DataIC50: 3.30E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347786(US9790220, Example 19)
Affinity DataIC50: 3.60E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347793(US9790220, Example 27 | US9790220, Example 26)
Affinity DataIC50: 6.00E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347785(US9790220, Example 18)
Affinity DataIC50: 8.80E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347784(US9790220, Example 17)
Affinity DataIC50: 9.60E+3nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347778(US9790220, Example 11)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347777(US9790220, Example 10)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347780(US9790220, Example 13)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347779(US9790220, Example 12)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347790(US9790220, Example 23)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347774(US9790220, Example 7)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347789(US9790220, Example 22)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347773(US9790220, Example 6)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347792(US9790220, Example 25)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347776(US9790220, Example 9)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347791(US9790220, Example 24)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347769(US9790220, Example 1)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347788(US9790220, Example 21)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347787(US9790220, Example 20)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347771(US9790220, Example 3)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347782(US9790220, Example 15)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM347781(US9790220, Example 14)
Affinity DataIC50: 1.00E+4nMAssay Description:Orexin antagonist activity was determined by measuring changes in intracellular calcium levels using a Ca2+ sensitive fluorescent dye. The changes in...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent